Dudediligence.

Novavax, Inc

NVAXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$84.5MSep ’24$88.3MDec ’24$666.7MMar ’25$239.2MJun ’25$70.4MSep ’25$147.1MDec ’25$139.5MMar ’26$56.7MJun ’26
Net income, by quarter
−$121.3MSep ’24−$81.0MDec ’24$518.6MMar ’25$106.5MJun ’25−$202.4MSep ’25$17.5MDec ’25−$9.5MMar ’26−$53.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$1.15B$1.98B$983.7M$682.2M$1.12B
Gross profit$1.15B$1.08B$639.9M$479.4M$1.05B
Operating income−$1.69B−$644.7M−$566.5M−$248.9M$452.8M
Net income−$1.74B−$657.9M−$545.1M−$187.5M$440.3M
Operating cash flow$322.9M−$415.9M−$714.0M−$87.3M−$244.6M
Free cash flow$268.4M−$505.0M−$767.7M−$100.3M−$250.2M
Cash$1.52B$1.34B$568.5M$530.2M$240.6M
Debtnone on filenone on filenone on filenone on file$244.2M
Shares outstanding75.8M86.0M139.5M160.4M162.6M
NVAX fundamentals · DudeDiligence